Skip to main content

Oligoarticular Juvenile Idiopathic Arthritis clinical trials at University of California Health

1 research study open to eligible people

Showing trials for
  • Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

    open to eligible people ages 2-16

    This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.

    at UCSF

Last updated: